A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)

KN Chi; S Taavitsainen; N Iqbal; C Ferrario; M Ong; D Wadhwa; SJ Hotte; G Lo; B Tran; A Azad; L Wood; JR Gingerich; S North; CV Pezaro; D Ruether; SS Sridhar; M Annala; J Bacon; AW Wyatt

Conference Proceedings

A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)

KN Chi, S Taavitsainen, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, G Lo, B Tran, A Azad, L Wood, JR Gingerich, S North, CV Pezaro, D Ruether, SS Sridhar, M Annala, J Bacon, AW Wyatt

Annals of Oncology | OXFORD UNIV PRESS | Published : 2018

DOI: 10.1093/annonc/mdy284.001

University of Melbourne Researchers

Arun Azad Author The Sir Peter MacCallum Department of Oncology

Ben Tran Author The Sir Peter MacCallum Department of Oncology

Grants

Funding Acknowledgements

Sanofi Genzyme, Prostate Cancer Canada Movember Disxcovery Grant, Canadian Institutes of Health Research Project Grant, Terry Fox Research Institute Program Project Grant.